Sprint Bioscience AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	87.99	97.29	-19.67	-0.85	-60.74	-25.63
Depreciation & Amortization	1.08	1.07	0.96	0.45	0.62	0.59
Other Adjustments	-4.42	-5.56	1.39	0.41	0.57	0.49
Change in Receivables	3.36	6.02	-4.25	-2.55	-0.09	-0.1
Changes in Accounts Payable	-2.03	-1.04	-0.23	2.02	0.84	-0.43
Changes in Other Operating Activities	-15.49	-14.26	-1.56	23.39	-0.25	-15.04
Operating Cash Flow	70.48	83.53	-23.36	22.87	-59.05	-40.12
Capital Expenditures	-0.07	-0.09	-1.3	-2.45	0	-2.71
Purchases of Investments	0.04	0.04	0	-	-	-
Investing Cash Flow	-0.03	-0.05	-1.3	-2.45	0	-2.71
Long-Term Debt Issued	-	-	-	-	-	10
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	10
Issuance of Common Stock	23.51	23.45	0	0	22.41	88.8
Net Common Stock Issued (Repurchased)	23.51	23.45	0	0	22.41	88.8
Other Financing Activities	-5.34	-5.28	-0.23	0.02	-4.51	-12.41
Financing Cash Flow	18.17	18.17	-0.23	0.02	17.9	86.39
Net Cash Flow	88.63	101.65	-24.88	20.44	-41.15	43.57
Free Cash Flow	70.42	83.44	-24.65	20.42	-59.05	-42.82
Free Cash Flow Growth	-15.61%	-	-	-	-	-
FCF Margin	45.91%	49.77%	-36.56%	37.59%	-13211.20%	-122.10%
Free Cash Flow Per Share	0.69	0.90	-0.35	0.29	-1.40	-1.48
Levered Free Cash Flow	-32.31	77.42	-20.4	22.97	-58.96	-32.67
Unlevered Free Cash Flow	71.48	82.97	-21.8	22.56	-59.53	-43.22